Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Clinical trial NCT06047379 · RECRUITING

Trial details

NCT number: NCT06047379
Sponsor: Neonc Technologies, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Astrocytoma, IDH-Mutant Glioblastoma, IDH-wildtype Brain Metastases, Adult Cervical Cancer Colorectal Cancer Esophageal Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Head and Neck Squamous Cell Carcinoma Melanoma Merkel Cell Carcinoma

Start date: 2023-11-01
Primary completion: 2027-02-28
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.